COVID-19 vaccine effectiveness
(Randomized evidence)

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04510207, ChiCTR2000034780
Sinopharm-Wuhan
Al Kaabi N, JAMA, 2021 ()

Full text
Commentary
Commentary
Inactivated virus

WIBP-CorV

Adjuvant

RCT
Phase 3
Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain N=26941
Some concerns
Details

Full description

NCT04510207, ChiCTR2000034780
Sinopharm-Beijing
Al Kaabi N, JAMA, 2021 ()

Full text
Commentary
Commentary
Inactivated virus

BBIBP-CorV

Adjuvant

RCT
Phase 3
Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain N=26941
Some concerns
Details

Full description

ChiCTR2000031809
Sinopharm-Wuhan
Guo W, EClinicalMedicine, 2021 ()

Full text
Commentary
Inactivated virus

WIBP-CorV 5 mcg D0/21

Adjuvant

RCT
Phase 1-2
Healthy adults with no history of COVID-19 at 5 centers in China. N=1120
Some concerns
Details

Full description

ChiCTR2000031809
Sinopharm-Wuhan
Xia S, JAMA, 2020 ()

Full text
Commentary
Inactivated virus

WIBP-CorV 5mcg-D0/21

Placebo

RCT
Phase 2
Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test N=224
Some concerns
Details

Full description